Abstract
Novel approaches to prevent delirium are needed. Metformin has been reported to improve age‐related disorders, including dementia, and to lower mortality. Furthermore, anti‐inflammatory drugs attenuate inflammation, which is thought to be a risk of delirium. Thus, we hypothesized that metformin or anti‐inflammatory drug exposure would be associated with reduced prevalence of delirium and lower risk of mortality.
We conducted retrospective cohort studies using data from our previous studies. It was found that a history of metformin use reduced the risk of delirium and the risk of 3‐year mortality in patients with a type 2 diabetes mellitus. It was also found that a history of NSAIDs use tended to reduce the risk of delirium and decreased risk of one‐year mortality. These data showed the potential benefit of metformin and NSAIDs on delirium risk and mortality.
